Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.

The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.

New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.

Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.

The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.

TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.